ONCOBONE VENTURES ANNOUNCES COLLABORATION WITH METASTASIS SPECIALIST MESTASTOP SOLUTIONS
OncoBone Ventures (www.oncoboneventures.com), the UK start-up biotech company seeking to develop novel therapies for cancer patients with currently incurable bone metastases, is pleased to announce that it has signed a collaboration agreement with India-based Mestastop Solutions Pvt. Ltd (“Mestastop”) (www.mestastop.com), a pioneer in the metastasis field.
Mestastop has dissected the whole metastasis process in three patent protected platforms METAssay®, METSCAN® and METVivo® that they can use to identify cancer patients who are at a higher risk of metastasis, as well as pertinent targets for drug discovery.
Arnab and Debabani Roy Chowdhury, Founders and Directors of Mestastop state: “We were happy to partner with OncoBone Ventures, who are focused on developing novel therapies for cancer patients with bone metastases, for whom there are currently no effective therapies available. The collaboration includes developing novel in vitro models as a screening platform for evaluating efficacy of therapies on cancer bone metastases.”
Tiina Kähkönen, Founder and CSO of OncoBone Ventures comments: “We have been truly fortunate to find a collaborator like Mestastop Solutions who shares our passion to develop therapies for cancer patients with metastatic disease. Together we have the required expertise to successfully develop a pioneering in vitro bone metastasis platform that will be of great importance for the development of novel therapies affecting bone metastases.”
Jussi Halleen, Founder and CEO of OncoBone Ventures adds: “OncoBone Ventures aims to utilize the developed in vitro platform as a screening tool before testing efficacy of our pipeline assets in our current in vivo Bone Metastasis Technology Platform. This will lead to faster and more cost-effective development of efficient therapies for patients with bone metastases.
About OncoBone Ventures
OncoBone Ventures is a UK start-up biotech company seeking to develop novel therapies for cancer patients with currently incurable bone metastases. Working together with its wholly owned Finland-based subsidiary OncoBone Therapeutics, the Company will see the utilisation of its novel osteoimmuno-oncology (OIO) concept and preclinical Bone Metastasis Technology Platform to guide the development of effective and safe immunotherapies for cancer patients with bone metastases.
Bone metastases provide a high unmet clinical need. About 70-80% of advanced breast and prostate cancer patients develop bone metastases and there are no effective treatments currently available. Furthermore, bone metastases often decrease quality of life, are painful and can cause severe bone complications, such as spinal cord compression and fractures.
